Molecular insights into substrate specificity of prostate specific antigen through structural modeling

Proteins: Structure, Function and Bioinformatics

Volumn 77, Issue 4, 2009, Pages 984-993

  Singh, Pratap ^a   LeBeau, Aaron M ^b   Lilja, Hans ^c   Denmeade, Samuel R ^a,d   Isaacs, John T ^a,d  

^a Whiting School of Engineering   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^d JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Aldehyde inhibotors; Cancer; Enzyme; HSSKLQ; Hydrolysis; Peptide inhibitors; Positional scanning; Prostate; PSA; Virtual scanning

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; PROTEIN INHIBITOR;

ANTIGEN STRUCTURE; ARTICLE; BINDING AFFINITY; BINDING SITE; ENZYME ACTIVITY; ENZYME CONFORMATION; ENZYME SPECIFICITY; HYDROLYSIS; MOLECULAR MODEL; NONHUMAN; PATHOLOGY; PEPTIDE SYNTHESIS; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN CONFORMATION;

ALGORITHMS; AMINO ACID SEQUENCE; CATALYTIC DOMAIN; COMPUTER SIMULATION; HUMANS; HYDROLYSIS; KINETICS; LIGANDS; MALE; MODELS, MOLECULAR; MOLECULAR STRUCTURE; OLIGOPEPTIDES; PEPTIDE FRAGMENTS; PROSTATE-SPECIFIC ANTIGEN; PROTEIN CONFORMATION; SERINE PROTEINASE INHIBITORS; SUBSTRATE SPECIFICITY;

EID: 70450046333     PISSN: 08873585     EISSN: 10970134     Source Type: Journal    
DOI: 10.1002/prot.22524     Document Type: Article

References (31)

1. Watt KW, Lee PJ, M'Timkulu T, Chan WP, Loor R. Human prostate-specific antigen: structural and functional similarity with serine proteases. Proc Natl Acad Sci USA 1986;83:3166-3170. (Pubitemid 16042997)
2. Borgono CA, Diamandis EP. The emerging roles of human tissue kallikreins in cancer. Nat Rev Cancer 2004;4:876-890. (Pubitemid 39472954)
3. Hara M, Koyanagi Y, Inoue T, Fukuyama T. [Some physico-chemical characteristics of "seminoprotein," an antigenic component specific for human seminal plasma. Forensic immunological study of body fluids and secretion VII] Nippon Hoigaku Zasshi 1971;25:322-324.
4. Williams SA, Singh P, Isaacs JT, Denmeade SR. Does PSA play a role as a promoting agent during the initiation and/or progression of prostate cancer? Prostate 2006;67:312-329.
5. Lilja H. A kallikrein-like serine protease in prostatic fluid cleaves the predominant seminal vesicle protein. J Clin Invest 1985;76:1899-1903. (Pubitemid 16196061)
6. Malm J, Hellman J, Hogg P, Lilja H. Enzymatic action of prostate-specific antigen (PSA or hK3): substrate specificity and regulation by Zn(21), a tight-binding inhibitor. Prostate 2000;45:132-139.
7. Killian CS, Corral DA, Kawinski E, Constantine RI. Mitogenic response of osteoblast cells to prostate-specific antigen suggests an activation of latent TGF-beta and a proteolytic modulation of cell adhesion receptors. Biochem Biophys Res Commun 1993;192:940-947. (Pubitemid 23227414)
8. Robertson SA. Seminal plasma and male factor signalling in the female reproductive tract. Cell Tissue Res 2005;322:43-52.
9. Cohen P, Graves HC, Peehl DM, Kamarei M, Giudice LC, Rosenfeld RG. Prostate-specific antigen (PSA) is an insulin-like growth factor binding protein-3 protease found in seminal plasma. J Clin Endocrinol Metab 1992;75:1046-1053.
10. Chan JM, Stampfer MJ, Giovannucci E, Gann PH, Ma J, Wilkinson P, Hennekens CH, Pollak M. Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science 1998;279:563-566. (Pubitemid 28067285)
11. Nelson JB, Hedican SP, George DJ, Reddi AH, Piantadosi S, Eisenberger MA, Simons JW. Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate. Nat Med 1995;1:944-949.
12. Shah RB, Mehra R, Chinnaiyan AM, Shen R, Ghosh D, Zhou M, Macvicar GR, Varambally S, Harwood J, Bismar TA, Kim R, Rubin MA, Pienta KJ. Androgen-independent prostate cancer is a heterogeneous group of diseases: lessons from a rapid autopsy program. Cancer Res 2004;64:9209-9216. (Pubitemid 39665537)
13. Otlewski J, Jaskolski M, Buczek O, Cierpicki T, Czapinska H, Krowarsch D, Smalas AO, Stachowiak D, Szpineta A, Dadlez M. Structure-function relationship of serine protease-protein inhibitor interaction. Acta Biochim Pol 2001;48:419-428. (Pubitemid 33638625)
14. Perona JJ, Craik CS. Structural basis of substrate specificity in the serine proteases. Protein Sci 1995;4:337-360.
15. Singh P, Williams SA, Shah MH, Lectka T, Pritchard GJ, Isaacs JT, Denmeade SR. Mechanistic insights into the inhibition of prostate specific antigen by beta-lactam class compounds. Proteins 2008;70:1416-1428. (Pubitemid 351304100)
16. Huang X, Knoell CT, Frey G, Hazegh-Azam M, Tashjian AH, Jr, Hedstrom L, Abeles RH, Timasheff SN. Modulation of recombinant human prostate-specific antigen: activation by Hofmeister salts and inhibition by azapeptides. Appendix: thermodynamic interpretation of the activation by concentrated salts. Biochemistry 2001;40:11734-11741.
17. Denmeade SR, Lou W, Lovgren J, Malm J, Lilja H, Isaacs JT. Specific and efficient peptide substrates for assaying the proteolytic activity of prostate-specific antigen. Cancer Res 1997;57:4924-4930. (Pubitemid 27469004)
18. Singh P, Williams SA, Shah MH, Leckta T, Pritchard GJ, Isaacs JT, Denmeade SR. Mechanistic insights into the inhibition of prostate specific antigen by b-lactam class compounds (DOI: 10.1002/prot.21676). Proteins 2008;70:1416-1428.
19. Coombs GS, Bergstrom RC, Pellequer JL, Baker SI, Navre M, Smith MM, Tainer JA, Madison EL, Corey DR. Substrate specificity of prostate-specific antigen (PSA). Chem Biol 1998;5:475-488. (Pubitemid 28436726)
20. Villoutreix BO, Getzoff ED, Griffin JH. A structural model for the prostate disease marker, human prostate-specific antigen. Protein Sci 1994;3:2033-2044.
21. LeBeau AM, Singh P, Isaacs JT, Denmeade SR. Potent and selective peptidyl boronic acid inhibitors of the serine protease prostate-specific antigen. Chem Biol 2008;15:665-674. (Pubitemid 351957911)
22. Jones G, Willett P, Glen RC. Molecular recognition of receptor sites using a genetic algorithm with a description of desolvation. J Mol Biol 1995;245:43-53.
23. Jones G, Willett P, Glen RC, Leach AR, Taylor R. Development and validation of a genetic algorithm for flexible docking. J Mol Biol 1997;267:727-748. (Pubitemid 27170693)
24. Czapinska H, Helland R, Smalas AO, Otlewski J. Crystal structures of five bovine chymotrypsin complexes with P1 BPTI variants. J Mol Biol 2004;344:1005-1020. (Pubitemid 39491246)
25. Kramer A, Reineke U, Dong L, Hoffmann B, Hoffmuller U, Winkler D, Volkmer-Engert R, Schneider-Mergener J. Spot synthesis: observations and optimizations. J Pept Res 1999;54:319-327.
26. Kappel JC, Barany G. Backbone amide linker (BAL) strategy for Nalpha-9-fluorenylmethoxycarbonyl (Fmoc) solid-phase synthesis of peptide aldehydes. J Pept Sci 2005;11:525-535. (Pubitemid 41195242)
27. Perona JJ, Craik CS. Evolutionary divergence of substrate specificity within the chymotrypsin-like serine protease fold. J Biol Chem 1997;272:29987-29990.
28. Lee DL, Powers JP, Pflegerl K, Vasil ML, Hancock RE, Hodges RS. Effects of single D-amino acid substitutions on disruption of betasheet structure and hydrophobicity in cyclic 14-residue antimicrobial peptide analogs related to gramicidin S. J Pept Res 2004;63:69-84. (Pubitemid 38333836)
29. Debela M, Magdolen V, Schechter N, Valachova M, Lottspeich F, Craik CS, Choe Y, Bode W, Goettig P. Specificity profiling of seven human tissue kallikreins reveals individual subsite preferences. J Biol Chem 2006;281:25678-25688. (Pubitemid 44401957)
30. Neidhart D, Wei Y, Cassidy C, Lin J, Cleland WW, Frey PA. Correlation of low-barrier hydrogen bonding and oxyanion binding in transition state analogue complexes of chymotrypsin. Biochemistry 2001;40:2439-2447. (Pubitemid 32171717)
31. Krishnan R, Zhang E, Hakansson K, Arni RK, Tulinsky A, Lim-Wilby MS, Levy OE, Semple JE, Brunck TK. Highly selective mechanism-based thrombin inhibitors: structures of thrombin and trypsin inhibited with rigid peptidyl aldehydes. Biochemistry 1998;37:12094-12103. (Pubitemid 28411293)